Canaccord analyst William Plovanic lowered the firm’s price target on Neuronetics (STIM) to $7 from $8 and keeps a Buy rating on the shares. The firm said they reported a Q2 beat driven by Clinic/Greenbrook revenue. Management reiterated its revenue guidance but brought down its Ggross margin guidance in light of Clinic revenue becoming a bigger mix of the business.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STIM: